for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

North China Pharmaceutical Co., Ltd.

600812.SS

Latest Trade

9.10CNY

Change

-1.01(-9.99%)

Volume

139,445,896

Today's Range

9.10

 - 

10.37

52 Week Range

3.89

 - 

10.37

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
10.11
Open
10.33
Volume
139,445,896
3M AVG Volume
906.67
Today's High
10.37
Today's Low
9.10
52 Week High
10.37
52 Week Low
3.89
Shares Out (MIL)
1,630.80
Market Cap (MIL)
16,487.44
Forward P/E
--
Dividend (Yield %)
0.30

Latest Developments

More

North China Pharmaceutical's Board Elects Yang Guozhan As Chairman

North China Pharmaceutical sees H1 2018 net profit up about 100 pct

North China Pharmaceutical to set up unit for vitamin c powder and organic phosphate project

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About North China Pharmaceutical Co., Ltd.

North China Pharmaceutical Co., Ltd. is a China based company principally engaged in the research and development, production and sales of pharmaceuticals. The Company is mainly engaged in the research and development, production and sales of chemical raw materials, chemical preparations, biological preparations, pharmaceutical intermediates and nutraceuticals. The Company's products are covered in infective drugs, biotech drugs, cardio cerebrovascular drugs, nephropathy and immunomodulatory drugs, cancer therapeutic drugs, vitamins and nutraceuticals. In addition, The Company is also engaged in pharmaceutical logistics business. The Company distributes its products within the domestic market and to overseas markets.

Industry

Biotechnology & Drugs

Contact Info

No. 388, Heping East Road

+86.311.86691718

http://www.ncpc.com

Executive Leadership

Haijing Yang

Chairman of the Board, Finance Director, Chief Accounting Officer, Secretary of the Board

Wenfu Liu

Vice Chairman of the Board, General Manager

Guitong Liu

Deputy General Manager, Director

Renlong Gao

Deputy General Manager

Jie Tong

Deputy General Manager

Key Stats

Price To Earnings (TTM)
97.97
Price To Sales (TTM)
1.68
Price To Book (MRQ)
3.01
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
185.20
LT Debt To Equity (MRQ)
37.92
Return on Investment (TTM)
2.21
Return on Equity (TTM)
0.94

Latest News

BRIEF-North China Pharmaceutical receives GMP certificate

* Says it received goods manufacture practice (GMP) certificate from Hebei Food and Drug Administration

BRIEF-North China Pharmaceutical receives GMP certificate

* Says it received goods manufacture practice (GMP) certificate from Hebei Food and Drug Administration on Feb. 6

BRIEF-North China Pharmaceutical sees FY 2017 net profit down 50 pct to 70 pct

* Sees FY 2017 net profit to decrease by 50 percent to 70 percent, or to decreased by 27 million yuan to 38 million yuan

BRIEF-North China Pharmaceutical to issue up to 2 bln yuan commercial paper

* Says it plans to issue up to 2.0 billion yuan ($302.20 million) commercial paper

BRIEF-North China Pharmaceutical issues 2017 second tranche corporate bonds worth 290 mln yuan

* Says it issued 2017 second tranche corporate bonds worth 290 million yuan

BRIEF-North China Pharmaceutical sets coupon rate of 2017 2st tranche corporate bonds at 6.2 pct

* Says it sets coupon rate of 2017 2st tranche corporate bonds at 6.2 percent

BRIEF-North China Pharmaceutical to issue 290 mln yuan 4-year bonds

* Says to issue 290 million yuan ($43.97 million) 4-year bonds

BRIEF-North China Pharmaceutical to pay A shares annual div for FY 2016 on Aug. 25

* Says it will pay cash dividend of 0.02 yuan(before tax)/share for 2016 to shareholders of record on Aug. 24

BRIEF-North China Pharmaceutical issues 2017 2nd series super short-term debentures worth 500 mln yuan

* Says it issues 2017 the second series super short-term debentures worth 500 million yuan, with coupon rate of 5.08 percent and maturity date on Jan. 29, 2018

BRIEF-North China Pharmaceutical issues 210 mln yuan worth of corporate bonds

* Says it issues 210 mln yuan worth of 2017 public offering corporate bonds

BRIEF-North China Pharmaceutical sets coupon rate for 2017 corporate bonds at 6.5 pct

* Says it sets coupon rate for 2017 corporate bonds at 6.5 percent

BRIEF-North China Pharmaceutical to issue up to 500 mln yuan 4-year bonds

* Says to issue up to 500 million yuan ($74.10 million) 4-year bonds

BRIEF-North China Pharmaceutical's unit receives GMP certificate

* Says co's pharmacy unit received goods manufacture practice (GMP) certificate from Hebei Food and Drug Administration, for its sterile APIs (amoxicillin/sulbactam), with the valid period is until June 22, 2022

BRIEF-North China Pharma gets approval to issue 2.0 bln yuan debt financing instruments

* Says it gets approval to issue 2.0 billion yuan ($294.94 million) debt financing instrument

BRIEF-North China Pharmaceutical unit receives GMP certificate

* Says co's unit received goods manufacture practice (GMP) certificate from Guangdong Food and Drug Administration for its powder injection production line

BRIEF-North China Pharmaceutical issues 2017 1st tranche super short-term financing notes worth 1 bln yuan

* Says it issued 2017 1st tranche super short-term financing notes worth 1 billion yuan with a term of 270 days and interest rate of 5.3 percent

BRIEF-North China Pharmaceutical receives GMP certificate

* Says it received goods manufacture practice (GMP) certificate from Shijiazhuang Food and Drug Administration

BRIEF-North China Pharmaceutical unit gets Certificate of Suitability to Monograph of European Pharmacopoeia

* Says wholly owned unit received Certificate of Suitability to Monograph of European Pharmacopoeia, from European Directorate for Quality of Medicines & HealthCare, for AMOXICILLIN TRIHYDRATE

BRIEF-Lock-up period for North China Pharma's 252.2 mln shares to end

* Says lock-up period for 252.2 million shares to end, shares to start trading on April 10

BRIEF-North China Pharmaceutical receives GMP certificate

* Says it received goods manufacture practice(GMP) certificate from Hebei Food and Drug Administration on March 21

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up